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ABSTRACT
As a membrane influx transporter, organic an-
ion-transporting polypeptide 1B1 (OATP1B1) regu-
lates the cellular uptake of a number of endogenous 
compounds and drugs. The aim of this study was to 
characterize the diversity of the solute carrier organic 
anion transporter family member 1B1 (SLCO1B1) 
gene encoding this transporter in two ethnic groups 
populating the Western Balkans. The distribution of 
SCLO1B1 alleles was determined at seven variant 
sites (c.388A>G, c.521T>C, c.571T>C, c.597C>T, 
c.1086C>T, c.1463G>C and c.*439T>G) in 266 
Macedonians and 94 Albanians using the TaqMan 
allelic discrimination assay. No significant difference 
in the frequencies of the single nucleotide polymor-
phisms (SNPs) was observed between these popu-
lations. The frequency of the c.521T>C SNP was 
the lowest (<13.7 and 12.2%, respectively), while 
the frequencies of all other SNP alleles were above 
40.0%. Variant alleles of c.1463G>C and c.1086 
C>T SNPs were not identified in either ethnic group. 
The haplotype analysis revealed 20 and 21 different 
haplotypes in the Macedonian and Albanian popula-
tion, respectively. The most common haplotype in 
both ethnic groups, *1J/*1K/*1L, had a frequency 
of 39.0% and 26.6%, respectively. In both popula-
tions, the variant alleles of the functionally significant 
c.521T>C and c.388A>G SNPs existed in one major 
haplotype (*15/*16/*17), with a frequency of 8.6 
and 2.4% in the Macedonian and Albanian subjects, 
respectively. In conclusion, sequence variations of 
the SLCO1B1 gene in the studied populations occur 
at high frequencies, which are similar to that of the 
Caucasian population. Further studies are needed to 
evaluate the clinical significance of these SNPs and/
or the major SLCO1B1 haplotypes they form for a 
large number of substrates and for susceptibility to 
certain diseases.
Keywords: Haplotypes; organic anion-trans-
porting polypeptide 1B1 (OATP1B1); solute car-
rier organic anion-transporter family member 1B1 
(SLCO1B1) gene; single nucleotide polymorphisms 
(SNPs); Western Balkan populations.
INTRODUCTION
Membrane influx and efflux transporters have 
a significant role in facilitating or preventing drug 
movement through biological membranes. Drug re-
sponses are largely dependent on their interplay with 
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phases I and II metabolism and the physicochemical 
properties of a drug. They function in the selective 
absorption and elimination of drugs, mediate tissue-
specific drug distribution and are also targets of many 
clinically used drugs. In addition, they play a critical 
role in the development of resistance to anticancer 
drugs, anticonvulsants and antiviral agents. When 
considering drug transport, two major super-families, 
ABC (ATP binding cassette) and SLC (solute carrier) 
transporters attract the highest scientific attention.
The SLC super family includes genes that en-
code facilitating transporters and ion-coupled sec-
ondary active transporters that reside in various cell 
membranes. Genes of the solute carrier organic anion 
transporter (SLCO) family encode organic anion-
transporting polypeptides (OATPs), membrane in-
flux transporters identified mostly in the intestine, 
liver, kidney, lung, testes, placenta and blood-brain 
barrier among other organs. The OATP1B1 [previ-
ously OATP2, OATP-C and liver specific transporter 
1 (LST-1)], expressed in the sinusoidal membrane of 
the hepatocytes, is known to be involved in the hepat-
ic uptake of a broad array of endogenous compounds 
(e.g., steroid conjugates, bile acids, eicosanoids and 
thyroid hormones) and drugs such as methotrexate, 
fexofenadine, repaglinide and statins [1-6]. Examples 
of in vitro OATP1B1 drug substrates include several 
HMG-CoA reductase inhibitors, angiotensin-convert-
ing enzyme inhibitors and angiotensin II receptor an-
tagonists [6-8]. Many drugs have also been identified 
in vitro as OATP1B1 inhibitors and there are some 
in vivo interactions where OATP1B1 inhibition can 
be regarded as an important mechanism. Examples 
include cyclosporine, atorvastatin, gemfibrozil and 
rifampicin [9,10].
The OATP1B1 protein is a 691-amino acid gly-
coprotein with 12 putative membrane-spanning do-
mains and a large fifth extracellular loop. Its encoding 
gene, solute carrier organic anion transporter family 
member 1B1 (SLCO1B1), is located on chromosome 
12 (gene locus 12p12) [11]. A large number of single 
nucleotide polymorphisms (SNPs), both non synony-
mous and synonymous, have been discovered in the 
SLCO1B1 gene, and several of these have proven 
to affect a substrate-dependent transport function 
in vitro and in vivo [12,13]. While no firm evidence 
for association between these SNPs and develop-
ment of certain diseases (e.g., gallstone develop-
ment, essential hypertension) due to dysregulation 
of endogenous compounds transport exists, there are 
numerous research data pointing to their effects on 
drugs responses.
The SNPs 388 (A>G) (*1b, rs2306283) and 
521 (C>T) (*5, rs4149056) are considered to be the 
most prevalent and most relevant variants, encod-
ing a substitution of alanine for valine at amino acid 
174 (p.Val174Ala), and amino acid change at po-
sition 130 (p.Asn130Asp), respectively. Increased 
transport activity of pravastatin as well as decreased 
plasma concentration of ezetimibe in carriers of the 
SLCO1B1*1b allele was observed [14,15], unlike 
reduced uptake of all statins except fluvastatin in 
hepatocytes and increased area under curve (AUC) 
of fexofenadine, repaglinide and irinotecan in carri-
ers of SLCO1B1*5 [3,4,16,17]. The carriers of the 
c.521T>C variant were also highlighted by a genome-
wide association study as a population with an in-
creased risk for simvastatin-induced myopathy be-
cause of the increased plasma and muscle exposure to 
statins [18]. These findings were further confirmed by 
Santos et al. [19], who suggested that the SLCO1B1 
genetic risk depends on the specific drug that was 
used. It was also shown that subjects carrying the 
SLCO1B1 c.388GG genotype exhibit significantly 
higher low-density-lipoprotein cholesterol reduction 
relative to c.388AA+ c.388AG carriers, pointing out 
that the SLCO 1B1 c.388A>G polymorphism may 
be used as an important marker for predicting the 
efficacy of a lipid-lowering therapy [20].
Recent data point out that these two variants are 
in linkage disequilibrium (LD) and exist in variable 
SLCO 1B1 haplotypes; AT, a haplotype known as *1A 
(reference haplotype), GT as *1B, AC as *5 and GC as 
*15, for c.388 A>G and c.521T>C, respectively [13]. 
The *15 haplotype has been consistently associated 
with a decreased transport activity, while controver-
sial results have been reported for the*1B haplotype 
[21]. It was also demonstrated that the SLCO1B1*17 
haplotype (g.-11187G>A, c.388G>A and c.521T>C) 
was associated with increased plasma concentrations 
of pravastatin in humans [22], while the *14 haplo 
type (c.388G-c.463A-c.521T) was characterized with 
enhanced response to fluvastatin [23].
It is becoming evident that the incidence of se-
quence variations in the SLCO1B1 gene is largely 
dependent on the ethnic background. The c.521T>C 
variant showed an allele frequency of approximate-
ly 10.0-15.0% in Asian populations, 10.0-20.0% 
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in Caucasians and 1.0-2.0% in African-American 
populations. The c.388A>G SNP showed an allele 
frequency of approximately 30.0-45.0% in Cauca-
sians, 70.0-80.0% in African-American/Sub-Saharan 
African populations and 60.0-90.0% in Asian popu-
lations [12,22,24-26]. Therefore, characterization of 
the genetic variation in this transporting gene is an 
important step towards understanding the individual 
variation in drugs-substrates responses and develop-
ing a personalized and safer drug therapy.
To the best of our knowledge, there is no evi-
dence about genotyping of OATP1B1 in the popula-
tions living in Western Balkans. Also, there is no 
evidence when considering the populations living in 
the whole Balkan Peninsula, with exception of one re-
port evaluating association between three SLCO1B1 
SNPs and statin response in the Greek population 
[27]. In this respect, there has not been any report on 
the genotype of SLCO1B1 allelic variants in Mace-
donian and Albanian populations who are considered 
Caucasians. The origin of the Macedonians and Al-
banians is a continuing matter of discussion among 
historians; they also showed unequivocal signs of a 
common genetic history. In addition, Western Balkan 
countries have always been a historical crossroads 
between Asia, Africa and Europe. Considering all the 
above, the overall aim was to analyze the diversity 
of the SLCO1B1 gene in selected ethnically diverse 
populations living in the Western Balkans [Repub-
lic of Macedonia (RoM) and Republic of Kosovo 
(RoK)]. In this article, the results from the allele and 
genotypic frequencies of the several known SNPs in 
the SLCO1B1 gene and the haplotypes they form are 
presented. The results from this study could serve 
as a baseline clinical data for dosing of all drugs 
substrates of OATAP1B1 and avoiding the adverse 
drug reactions.
MATERIALS AND METHODS
Subjects and Study Protocol. For the aim of this 
study, a total of 233 Caucasian patients (age 18-72 
years, average body mass index (BMI) 26.20 kg/m2, 
109 women and 124 men) with hypercholesterolemia 
type IIa or IIb, were selected randomly from the out-
patients evaluated for coronary heart disease at the 
University Clinic of Cardiology in Skopje (RoM) and 
the University Clinical Center in Prishtina, Clinic for 
Internal Diseases (RoK). Of these, 156 (66.95%) were 
Macedonians, 64 (27.47 %) Albanians, four (1.72%) 
Turks and nine (3.86%) Gypsies. Due to the low num-
ber of patients, the data for the groups of Turks and 
Gypsies are not presented in this paper. Therefore, 
the evaluated group of patients (220 individuals, 105 
female and 115 male patients) consisted of 70.91% 
Macedonians (n = 156, 73 women and 83 men) and 
29.09% Albanians (n = 64, 32 women and 32 men).
Initially, the study protocol was approved by 
the Ethics Committee of the Faculty of Pharmacy 
and Committee for Clinical Studies of the Faculty 
of Medicine, University “Ss. Cyril and Methodius” 
(UKIM), Skopje, RoM, and the Ethics Committee 
and Committee for Clinical Studies of the Faculty of 
Medicine, University in Prishtina, RoK. All partici-
pants received oral and written information and gave 
a written informed consent before entering the study. 
Exclusion criteria (note: not relevant for the results 
present in this study, but important for the overall 
aim of the research) included cancer in remission 
for period shorter than 5 years, Cushing syndrome, 
hyperthyroidism, positive hepatitis B surface antigen, 
hepatitis C virus antibody, fibromyalgia, myopathy, 
rhabdomyolysis, malabsorption syndrome, renal fail-
ure, liver disease, McArdle disease, women who are 
pregnant, nursing or have planned a pregnancy, drugs 
interacting at the level of SLCO1B1. Data for BMI, 
cigarette smoking, blood pressure, alcohol consump-
tion, physical activity and pharmacotherapy were also 
collected and recorded. To evaluate the frequency of 
genetic variations in genes encoding SLCO1B1, one 
blood sample was obtained from each participant for 
DNA extraction on the first day of the hospital visit.
In this study, 140 DNA samples obtained from 
the DNA bank of the Center for Biomolecular Anal-
ysis at the UKIM-Faculty of Pharmacy, Skopje, 
RoM, were also analyzed for the diversity of the 
SLCO1B1 gene. These samples were obtained from 
healthy individuals (of Caucasian ethnicity, 78.57% 
Macedonians, 21.43% Albanians, 79 males, aver-
age age 48.0 ± 12.9, BMI 26.16 kg/m2) selected by 
medical history, physical examination and routine 
laboratory tests before entering the study. Consider-
ing that there was no significant difference (p >0.05) 
in the allelic frequencies of SLCO1B1 variants and 
genotype distributions between healthy subjects and 
patient groups, statistical analysis was also performed 
on the total population consisted of 360 subjects, 
of which 73.89% were Macedonians (n = 266, 129 
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women and 137 men) and 26.11% Albanians (n = 94, 
42 women and 52 men).
Genomic DNA Extraction and Genotyp-
ing Procedures. Three mL venous blood samples 
drawn with EDTA as anticoagulant were collected 
and stored at 4 °C prior to DNA isolation. DNA iso-
lation was performed at the Center for Biomolecular 
Pharmaceutical Analyses, UKIM-Faculty of Phar-
macy, Skopje, RoM, using the Qiamp DNA Blood kit 
(Qiagen GmbH, Hilden, Germany) according to the 
manufacturer’s protocol. The samples were kept at 
–20 °C until further analysis. The SLCO1B1 SNPs to 
be genotyped were selected on the basis of literature 
data [6,13,20,28,29] and a previous study in which 
151 subjects were included [30]. The following vari-
ants in the SLCO1B1 gene were analyzed: c.388A>G 
(Asn130Asp, rs2306283), c.521T>C (Val174Ala, 
rs4149056), c.571T>C (Leu191Leu, rs414 9057), 
c.597C>T (Phe199Phe, rs2291075), c.1086C>T 
(Tyr362Tyr, rs57040246), c.1463G>C (Gly488Ala, 
rs5950 2379), c.*439T>G (rs4149087, the position 
is given with the first nucleotide 3’ of the stop codon 
(TAA) set to *1) using TaqMan allelic discrimination 
assay (Applied Bio-systems, Foster City, CA, USA).
Polymerase chain reaction was performed on the 
quantitative real-time PCR (q-PCR) system Mx3005P 
(Strata gene, La Jolla, CA, USA) using TaqMan ge-
notyping protocols (TaqMan®Drug Metabolizing 
assay; Applied Bio-systems) in total volume of 12.5 
µL under following conditions: one cycle of 2 min. 
at 50 °C, one cycle of 10 min. at 95 °C, and 50 cycles 
of 15 seconds at 92 °C and 1 min. at 60 °C.
Population Genetics and Statistical Analy-
sis. The study sample alleles and genotype frequen-
cies were estimated with a gene counting method. 
The agreement with Hardy-Weinberg equilibrium 
(HWE) of the observed genotypic distribution for 
the SLCO1B1 gene was tested with the χ2 test. The 
statistical analysis was carried out using the Statistical 
Package for the Social Sciences (SPSS Inc., Chicago, 
IL, USA) software (v. 19.0).
Genetic diversity was quantified between the 
members of the same ethnic population, between 
the ethnic populations, and between different ethnic 
populations and the global population. Population 
comparisons were also performed with the χ2 test of 
population differentiation. Odds ratios (ORs) were 
calculated with 95% confidence interval (95% CI). 
For multiple comparisons, Bonferroni’s post hoc 
test was used. Statistically significant differences 
were those where the p value was less 0.05. Link-
age disequilibrium for each pair of SNPs within each 
population was quantified (correlation r2 and coef-
ficient of linkage disequilibrium D’ values) to find 
the haplotypes in the study groups. The statistical 
analyses were carried out using the SHEsis software 
platform for the analysis of LD, haplotype construc-
tion and genetic association at polymorphism loci 
(http://analysis2.bio-x.cn/myAnalysis.php) [31]. The 
haplotypes were presented with their previously as-
signed names, as cited in the study of Pasanen et 
al. [13] in which allelic frequencies at 11 variant 
sites were determined (g.11187G>A, g.11110T>G, 
g.10499A>C, c.388A>G, c.411G>A, c.463C>A, 
c.521T>C, c.571T>C, c.597C>T, c.1929A>C and 
c.*439T>G). Considering that five of these SNPs 
and two other SNPs have been analyzed in the pres-
ent investigation, one haplotype has several names 
and there are haplotypes that we designated as new.
RESULTS
Genotypes and Allele Frequencies. Genetic 
variation of SLCO1B1 was studied in 360 subjects 
in total, both patients with hyperlipidemia type IIa 
or IIb and healthy subjects, of which 266 were of 
Macedonian and 94 of Albanian ethnicity. Observed 
genotypes and allelic frequencies of SLCO1B1 gene 
polymorphisms did not differ significantly (p >0.05) 
when comparing the data obtained from patients and 
healthy subjects (Table 1). In addition, the observed 
frequency distributions did not show significant de-
viations from HWE (p >0.05) in both populations of 
the two ethnic groups, the population of both patients 
and healthy subjects, confirming the random selec-
tion of the individuals, i.e., representativeness of the 
population samples being studied. Taking all this into 
consideration, genotype and allele frequencies for 
the total population of Macedonians and Albanians 
were estimated and the data are presented in Table 2.
Data for distribution of genotypes and allele 
frequencies of SLCO1B1 gene polymorphisms be-
tween females and males, including both patients 
and healthy subjects within each ethnic group, are 
presented in Table 3. No significant differences for 
all SLCO1B1 gene polymorphisms were observed 
between female and male subjects, both within each 
and between the two ethnic groups.
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Table 1. Allelic and genotypic frequencies of SLCO1B1 in patients with hyperlipidemia type IIa or IIb and healthy subjects.    
Ethnic Group Macedoniana Albanianb
Number of Subjects Patients (n=156) (%) Healthy Subjects(n=110) (%) Patients (n=64) (%)
Healthy Subjects
(n=30) (%)
Location/Positionc/dbSNP ID
Exon 4/c.388A>G/rs2306283
AA  54 (34.6)  34 (30.9)  20 (31.2)  9 (30.0)
AG  80 (51.3)  58 (52.7)  35 (54.7) 16 (53.3)
GG  22 (14.1)  18 (16.3)  9 (14.1)  5 (16.7)
p Valued 0.77369 0.94636
G allele 124 (40.0)  94 (42.7)  53 (41.4) 26 (43.3)
A allele 188 (60.0) 126 (57.3)  75 (58.6) 34 (56.7)
p Valuee 0.49074 0.80295
Exon 5/c.521T>C/rs4149056
CC  4 (2.6)  5 (4.5) –  1 (3.0)
CT  36 (23.1)  19 (17.3)  14 (21.9)  7 (23.3)
TT 116 (74.3)  86 (78.2)  50 (78.1) 22 (73.3)
p Valued 0.38218 0.33055
C allele  44 (14.1)  29 (13.2)  14 (11.0)  9 (15.0)
T allele 268 (85.9) 191 (86.8) 114 (89.0) 51 (85.0)
p Valuee 0.76116 0.42813
Exon 5/c.571T>C/rs4149057
CC  66 (42.3)  45 (41.0)  22 (34.4) 12 (40.0)
CT  71 (45.5)  53 (48.2)  22 (53.1) 15 (50.0)
TT  19 (12.2)  12 (11.0)  8 (12.5)  3 (10.0)
p Valued 0.89666 0.84958
C allele 203 (65.0) 143 (65.0)  78 (61.0) 39 (65.0)
T allele 109 (35.0)  77 (35.0)  50 (39.0) 21 (35.0)
p Valuee 0.98782 0.59224
Exon 5/c.597C>T/rs229107
CC  60 (38.5)  40 (36.4)  16 (25.0) 11 (36.7)
CT  67 (42.9)  50 (45.5)  35 (54.7) 14 (46.6)
TT  29 (18.6)  20 (18.2)  13 (20.3)  5 (16.7)
p Valued 0.91693 0.50617
T allele 125 (40.1)  90 (40.9)  61 (47.6) 24 (40.0)
C allele 187 (59.9) 130 (59.1)  67 (52.3) 36 (40.0)
p Valuee 0.84493 0.32550
Exon 8/c.1086C>T/rs57040246
CC 156 (100.0) 110 (100.0)  64 (100.0) 30 (100.0)
CT  0 (0.0)  0 (0.0)  0 (0.0)  0 (0.0)
TT  0 (0.0)  0 (0.0)  0 (0.0)  0 (0.0)
p Valued >0.05 >0.05
T allele  0 (0.0)  0 (0.0)  0 (0.0)  0 (0.0)
p Valuee >0.05 >0.05
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Table 2. Genetic variation of the SLCO1B1 gene in Macedonian and Albanian subjects.
Ethnic Group Macedoniana Albanianb
Number of Subjects
Observed
Frequency
n=266 (%)
Expected
Frequency by
HWE (%)
p Valuec
Observed
Frequency
n=94 (%)
Expected
Frequency by
HWE (%)
p Valuec
Positiond/dbSNP ID
c.388A>G/rs2306283
AA  88 (33.1) 34.8  29 (30.8) 33.6
AG 138 (51.9) 48.4 0.99737  51 (54.2) 48.7 0.99358
GG  40 (15.0) 16.8  14 (14.9) 17.7
p Valuee 0.91299
G allele 218 (40.9)  79 (42.0)
A allele 314 (59.0) 109 (58.0)
p Valuef 0.80266
c.521T>C/rs4149056
CC  9 (3.4)  1.9  1 (1.1)  1.5
CT  55 (20.7) 23.7 0.99200  21 (22.3) 21.5 0.99919
TT 202 (75.9) 74.4  72 (76.6) 77.0
p Valuee 0.48666
C allele  73 (13.7)  23 (12.2)
T allele 459 (86.3) 165 (87.8)
p Valuef 0.60597
Exon 10/c.1463G>C/rs59502379
CC  0 (0.0)  0 (0.0)  0 (0.0)  0 (0.0)
CG  0 (0.0)  0 (0.0)  0 (0.0)  0 (0.0)
GG 156 (100.0)  58 (100.0)  64 (100.0) 30 (100.0)
p Valued >0.05 >0.05
C allele  0 (0.0)  0 (0.0)  0 (0.0)  0 (0.0)
p Valuee >0.05 >0.05
3’UTR/c.*439T>G/rs4149087
GG  32 (20.5)  28 (25.45)  15 (23.4)  9 (30.0)
GT  81 (51.9)  50 (45.45)  31 (48.4) 16 (53.3)
TT  43 (27.6)  32 (29.1)  18 (28.1)  5 (16.7)
p Valued 0.52208 0.46337
G allele 145 (46.5) 106 (48.2)  61 (47.7) 34 (56.7)
T allele 167 (53.5) 114 (51.8)  67 (52.3) 26 (43.3)
p Valuee 0.69853 0.24882
dbSNP: database of single nucleotide polymorphism; 3’UTR: 3’ untranslated region; NCBI: National Center for Biotechnology Information.
a Macedonians populating the RoM.
b Albanians populating the RoM and RoK.
c The positions of SNPs are given in relation to the NCBI reference sequences NM_006446.2 (cDNA; c.) with the fist nucleotide of the ATG first 
codon set to 1 and the nucleotide 5’ of ATG set to –1. The position of c.*439 is given with the first nucleotide 3’ of the stop codon (TAA) set to *1.
d The p value for the differences of genotype distributions between the patients and healthy subjects within the ethnic group.
e The p value for the differences of allelic frequencies between the patients and healthy subjects within the ethnic group.
Table 1. Continued
Continue
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c.571T>C/rs4149057
CC 111 (41.7) 42.3  34 (36.2) 38.7
CT 124 (46.6) 45.5 0.99969  49 (52.1) 47.0 0.99408
TT  31 (11.6) 12.2  11 (11.7) 14.3
p Valuee 0.61507
C allele 346 (65.0) 117 (62.2)
T allele 186 (35.0)  71 (37.8)
p Valuef 0.49039
c.597C>T/rs229107
CC 100 (37.6) 35.5  27 (28.7) 30.0
CT 117 (44.0) 48.2 0.99625  49 (52.1) 49.5 0.99864
TT  49 (18.4) 16.3  18 (19.1) 20.4
p Valuee 0.27697
T allele 215 (40.4)  85 (45.2)
C allele 317 (59.6) 103 (54.8)
p Valuef 0.25125
c.1086C>T/rs57040246
CC 266 (100.0) 100.0  94 (100.0) 100.0
CT  0 (0.0)  0.0 >0.05  0 (0.0)  0.0 >0.05
TT  0 (0.0)  0.0  0 (0.0)  0.0
p Valuee >0.05
T allele  0 (0.0)  0.0  0 (0.0)
p Valuef >0.05
c.1463G>C/rs59502379
CC  0 (0.0)  0 (0.0)  0 (0.0)  0 (0.0)
CG  0 (0.0)  0 (0.0) >0.05  0 (0.0)  0 (0.0) >0.05
GG 266 (100.0) 100.0  94 (100.0) 100.0
p Valuee >0.05
C allele  0 (0.0)  0 (0.0)
p Valuef >0.05
c.*439T>G/rs4149087
GG  60 (22.5) 25.5  24 (25.5) 22.2
GT 131 (49.2) 50.0 0.99993  47 (50.0) 49.8 1.0000
TT  75 (28.2) 24.5  23 (24.5) 27.9
p Valuee 0.73126
G allele 251 (47.2)  95 (50.5)
T allele 281 (52.8)  93 (49.5)
p Valuef 0.42917
HWE: Hardy-Weinberg equilibrium; dbSNP: database of single nucleotide polymorphism; 3’UTR: 3’ untranslated region; NCBI: National Center 
for Biotechnology Information.
a Macedonians populating the RoM.
b Albanians populating the RoM and RoK.
c The p value for the differences between observed and expected frequencies of genotype distributions within the ethnic group.
d The positions of SNPs are given in relation to the NCBI reference sequences NM_006446.2 (cDNA; c.) with the fist nucleotide of the ATG first 
codon set to 1 and the nucleotide 5’ of ATG set to –1. The position of c.*439 is given with the first nucleotide 3’ of the stop codon (TAA) set to *1.
e The p value of differences in genotype distributions between the ethnic groups.
f The p value of allele frequencies between the ethnic groups.
Table 2. Continued
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Table 3. Distribution of genotype and allele frequencies of the SLCO1B1 gene polymorphisms in female and male groups 
separately, within each ethnic group. 
Ethnic Group Macedonian Albanian
Number of Subjects Females (n=129) (%) Males (n=137) (%) Females (n=42) (%) Males (n=52) (%)
Position/dbSNP ID
c.388A>G/rs2306283
AA  42 (32.6)  46 (33.6) 14 (33.3) 15 (28.8)
AG  65 (50.4)  73 (53.3) 24 (57.1) 27 (51.9)
GG  22 (17.0)  18 (13.1)  4 (9.5) 10 (19.2)
p Valuea 0.66841 0.41932
G allele 109 (42.2) 109 (39.8) 32 (38.1) 47 (45.2)
A allele 149 (57.8) 165 (60.2) 92 (61.9) 57 (54.8)
p Valueb 0.56309 0.32702
c.521T>C/rs4149056
CC  6 (4.6)  3 (2.2) –  1 (2.0)
CT  25 (19.4)  30 (21.9)  9 (21.4) 12 (23.1)
TT  98 (76.0) 104 (75.9) 33 (78.6) 39 (75.0)
p Valuea 0.49822 0.64576
C allele  37 (14.3)  36 (13.1)  9 (10.7) 14 (13.5)
T allele 221 (85.7) 238 (86.9) 75 (89.3) 90 (86.5)
p Valueb 0.68707 0.56765
c.571T>C/rs4149057
CC  53 (41.2)  58 (42.3) 14 (33.3) 20 (38.5)
CT  61 (47.3)  63 (46.0) 23 (54.8) 26 (50.0)
TT  15 (11.6)  16 (11.7)  5 (11.9)  6 (11.5)
p Valuea 0.97571 0.82901
C allele 167 (64.7) 179 (65.3) 51 (60.7) 66 (63.5)
T allele  91 (35.3)  95 (34.7) 33 (39.3) 38 (36.5)
p Valueb 0.88472 0.69928
c.597C>T/rs229107
CC  49 (38.0)  51 (37.2) 12 (28.6) 15 (28.8)
CT  57 (44.2)  60 (43.8) 22 (52.4) 27 (51.9)
TT  23 (17.8)  26 (19.0)  8 (19.0) 10 (19.2)
p Valuea 0.97042 0.99902
C allele 103 (39.9) 112 (40.9) 38 (45.2) 47 (45.2)
T allele 155 (60.1) 162 (59.1) 46 (54.8) 57 (54.8)
p Valueb 0.82278 0.99500
c.1086C>T/rs57040246
CC 129 (100.0) 137 (100.0) 42 (100.0) 52 (100.0)
CT  0 (0.0)  0 (0.0)  0 (0.0)  0 (0.0)
TT  0 (0.0)  0 (0.0)  0 (0.0)  0 (0.0)
T allele  0 (0.0)  0 (0.0)  0 (0.0)  0 (0.0)
c.1463G>C/rs59502379
CC  0 (0.0)  0 (0.0)  0 (0.0)  0 (0.0)
CG  0 (0.0)  0 (0.0)  0 (0.0)  0 (0.0)
GG 129 (100.0) 137 (100.0)  42 (100.0) 52 (100.0)
C allele  0 (0.0)  0 (0.0)  0 (0.0)  0 (0.0)
Continue
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All SNPs, except c.1463G>C and c.1086C>T, 
occurred at an allele frequency higher than 12.0%. 
Variant alleles of SLCOB1 c.1463G>C and 
c.1086C>T polymor- phisms were not identified in 
either ethnic group in this study. The frequency of 
the c.521T>C SNP was the lowest, 13.7 and 12.2% 
for Macedonians and Albanians, respectively, while 
the frequencies of all other SNPs alleles were above 
40.0%, with frequency of the c.571T>C variant allele 
being highest in both populations (65.0 and 62.2% 
for Macedonians and Albanians, respectively). No 
significant differences (p >0.05) in allelic frequen-
cies and genotype distributions of the analyzed SNPs 
were observed between the two ethnic groups. The 
SNP variant allele frequencies in the ethnic groups 
separately compared to data reported from various 
ethnic groups are presented in Table 4.
Pairwise Linkage Disequilibrium. Pairwise 
LD profiles for single SNPs using r2 and D’ val-
ues for Macedonians and Albanians separately, are 
shown in Figures 1 and 2, respectively. Generally, 
the correlations of SNP pairs in the Albanian popu-
lation were weaker than those of the Macedonian 
population. The most strongly correlated (r2 ≥0.33) 
SNP pair in the Macedonian population was c.597 
C>T/c.388A>G (r2 = 0.531, D’ = 0.740), followed 
by c.597C>T/c.*439T>G (r2 = 0.373, D’ = 0.699). 
Other pairs showing a significant association were 
c.388A>G/c.*439 T>G (r2 = 0.289, D’ = 0.613) and 
c.521T>C/c.571T>C (r2 = 0.233, D’ = 0.919). The 
correlation of the most common SNP pair, c.388A>G/
c.521T>C, in the Macedonians was relatively weaker 
compared to other SNP pairs, with r2 = 0.113 and D’ 
= 0.698. The c.521T>C showed the strongest corre-
lation with c.571T>C, followed by c.597 C>T (r2 = 
0.178, D’ = 0.872), c.388A>G and c.*439 T>G (r2 
= 0.072, D’ = 0.645).
In the Albanian population, the same SNP pairs, 
c.597C>T/c.388A>G and c.597C>T/c.*439T>G, 
showed the strongest correlation with r2 = 0.221, 
D’ = 0.498 and r2 = 0.214, D’ = 0.505, respectively. 
The correlation between c.388 A>G and c.521T>C 
in the Albanian population was weaker (r2 = 0.009, 
D’ = 0.219) compared to the same SNP pairs in the 
Macedonian population. Similar data for the LD of 
c.521T>C with other SNPs were obtained, with the 
strongest correlation of this SNP with c.571T>C (r2 
= 0.091, D’ = 0.635), followed by c.597C>T (r2 = 
0.097, D’ = 0.746), c.388A>G and c.*439T>G (r2 = 
0.008, D’ = 0.238).
Haplotypes. The haplotype analysis revealed 20 
different haplotypes in the Macedonian population 
and 21 in the Albanian population (Tables 5 and 6). 
Nine haplotypes in each of the two populations were 
designated as new. Nine other haplotypes that oc-
curred in the Macedonian and Albanian populations 
had the same sequence of the actually investigated 
SNPs as in the newly identified haplotypes presented 
in the study of Pasanen et al. [13].
In the Macedonian population, eight haplotypes 
occurred at a frequency equal to or greater than 3.0% 
(Table 5). The most common haplotype in this ethnic 
group, *1J/ *1K/*1L, had a frequency of 39.0%, con-
taining variant allele C at position c.571 and having 
referent nucleotides at all other investigated posi-
tions. The variant allele C at position c.571 existed 
in eight haplotypes, with a frequency between 0.3 
and 39.0%. The variant allele G at position c.388 and 
T at c.597C>T SNP existed in 11, while the variant 
allele G at c.*439T>G in 12 haplotypes, all occur-
ring with frequencies between 0.3 and 11.6%. The 
c.521T>C SNP existed in six haplotypes, with a fre-
quency between 0.3 and 8.6%. The variant alleles of 
the functionally most distinguished SNPs, c.388A>G 
c.*439T>G/rs4149087
GG  30(23.3)  30 (21.9)  11 (26.2) 13 (25.0)
GT  64 (49.6)  67 (48.9)  19 (45.2) 28 (53.8)
TT  35 (27.1)  40 (29.2)  12 (28.6) 11 (21.2)
p Valuea 0.92239 0.64414
G allele 124 (48.1) 127 (46.4) 41 (48.8) 54 (51.9)
T allele 134 (51.9) 147 (53.6) 43 (51.2) 50 (48.1)
p Valueb 0.69266 0.67119
a The p value of differences in genotype distributions between females and males within the ethnic group.
b The p value of differences of allele frequencies between females and males within the ethnic group.
Table 3. Continued
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Table 4. Allelic frequencies of SLCO1B1 variants in Macedonians and Albanians compared to different ethnic populations.
Ethnic Group na c.388A>G c.521T>C c.571T>C c.597C>T c.1086C>T c.1463G>C c.*439T>G p Valueb p Valuec Refs.
American (African)
(European)
(Native)
 22
 49
 64
0.75
0.30
0.63
0.023
0.14
0.24
0.045
0.53
0.33
–
–
0.28
–
–
0.01
0.09
0.0
0.005
–
–
0.041
<0.00001
 0.812508
 0.000507
<0.00001
 0.675274
 0.003258
12
12
11
European
(Caucasian)
151
236
0.41
0.41
0.18
0.17
0.61
–
0.42
–
0.0
–
0.0
–
0.30
–
 0.118756
 0.466510
 0.149653
 0.328042
11
38
Sub-Saharan African 105 0.79 0.019 0.13 0.50 0.07 0.03 0.76 <0.00001 <0.00001 11
Oceanian  28 0.66 0.0 0.48 0.52 0.036 0.0 0.30  0.017744  0.055677 11
Algerian  29 0.64 0.17 0.21 0.59 0.017 0.0 0.72  0.004001  0.017564 11
Ugandan 115 0.78 0.039 0.061 0.0 – 0.02 – <0.00001 <0.00001 11
Indian (Asian)
North Indian
 35
100
0.60
0.57
0.071
0.065
–
0.44
–
0.22
0.0
0.0
–
–
–
–
 0.078203
 0.000010
 0.167511
 0.009301
24
25
Brazilian
(African)
(Mulatto)
(Caucasian)
(Amerindian) Brazilian
 97
332
603
182
143
–
–
–
–
0.26
0.057
0.15
0.15
0.28
0.14
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–  0.164989  0.136491
28
28
28
28
19
Chinese
178
100
 35
140
0.73
0.80
0.67
0.71
0.11
0.13
0.086
0.11
0.27
0.26
–
–
0.42
0.50
–
–
0.0
0.0
–
–
0.0
– 0.27–
<0.00001
<0.00001
 0.124778
 0.014801
<0.00001
<0.00001
 0.264367
 0.153581
11
25
24
39
Han Chinese 111 0.73 0.14 – – – – –  0.079881  0.339359 29
Uyghur (Chinese) 731 0.62 0.10 – – – – –  0.000925  0.119961 40
Finnish
(Caucasian)
468
193
0.46
–
0.20
–
0.53
–
0.46
–
–
0.0
–
0.0
0.49
–  0.038427  0.13401 13
Dutch  74 – 0.18 – – – – – 33
German (Caucasian) 300 0.37 0.15 0.35 0.38 – 0.0 –  0.002137  0.078291 36
Israeli 133 0.46 0.20 0.56 0.45 0.0 0.0 0.55  0.322641  0.571025 11
Japanese
120
267
 27
0.63
0.64
0.74
0.16
0.11
0.19
0.36
–
0.26
0.43
–
0.26
–
–
0.0
–
–
0.0
–
–
0.19
<0.00001
 0.011239
 0.001111
 0.005088
 0.195709
 0.003401
34
41
11
Korean  24 0.75 0.25 – – – – –  0.775142  1.00000 35
Malaysian 100 35
0.87
0.83
0.11
0.13
0.24
–
0.50
–
0.0
–
–
–
–
–
<0.00001
 0.186616
<0.00001
 0.403354
25
24
Pakistani 192 0.47 0.09 0.56 0.26 0.0 0.005 0.59  0.008402  0.81518 11
Tanzanian 366 0.87 0.06 – – – – – <0.00001  0.289424 38
Turkish  94 0.46 0.12 0.0.38 0.36 – 0.0 –  0.89754  0.289424 36
Macedonian 266 0.41 0.14 0.65 0.40 0.0 0.0 0.47  0.928464d this study
Albanian  94 0.42 0.12 0.62 0.45 0.0 0.0 0.50  0.928464 this study
Greek 403 0.43 0.16 – – – – –  0.811389  0.595368 27
Caucasian 423 0.37 0.15 – – – – –  0.472334  0.333625 32
a n: number of patients.
b The p value of differences in allele frequencies between Macedonians and different ethnic groups.
c The p value of differences in allele frequencies between Albanians and different ethnic groups.
d The p value of differences in allele frequencies between Albanians and Macedonians.
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and c.521T>C, were present in four haplotypes, of 
which the dominant haplotype *15/*16/*17 had a 
frequency of 8.6%.
In the Albanian population, 10 haplotypes oc-
curred at a frequency equal or greater than 3.0% 
(Table 6). The most common haplotype was the same 
as in the Macedonian ethnic group, *1J/*1K/*1L, 
with a frequency of 26.6%. The variant allele C at 
position c.571 existed in nine haplotypes with a fre-
quency between 1.4 and 26.6%. The variant allele 
G at position c.388 existed in 10 haplotypes, while 
c.597C>T SNP in 11 haplotypes, both occurring at 
frequencies between 1.0 and 12.4%. The c.*439T>G 
occurred in 10 haplotypes, with a frequency between 
0.6 and 12.4%, and the c.521T>C SNP existed in 
seven haplotypes, with a frequency between 0.6 and 
3.7%. Three of the haplotypes contained the vari-
ant alleles of the c.388A>G and c.521 T>C SNPs 
with a frequency ≥1.0%, with the major haplotype 
*15/*16/*17 having a frequency of 2.4%.
DISCUSSION
It is clearly evident that the mutations in the SL-
CO1B1 gene and their clinical significance for a large 
number of endogenous and xenobiotic substrates 
Table 5. Alignment and frequencies of the SLCO1B1 haplotypes in 266 Macedonian subjects.  
SLCO1B1 Haplotype c.388A>G
c.521
T>C
c.571
T>C
c.597
C>T
c.1086
C>T
c.1463
G>C
c.*439
T>G Haplotypes Found
Reference A T T C C G T n % 95% CI
*1J/*1K/*1La C 148 39.1 0.747-1.338
*18b/Newc G C T G  44 11.6 0.641-1.559
*15a/*16d/*17c G C T G  32  8.6 0.602-1.662
*1J/*1K/*1La C G  32  8.4 0.599-1.668
*1G/*1Ha/Newf/Newg G T G  29  7.7 0.587-1.705
*1Aa/Newf/*1Eh  22  5.9 0.548-1.25
*1B/*1Fa/Newf G G  11  3.1 0.441-2.265
*20i/*21j/Newf G T  11  3.0 0.432-2.315
New T G  8  2.1 0.375-2.667
*5a/Newf C G  7  2.0 0.360-2.779
New G C  7  1.9 0.353-2.836
*18k/Newl G C T  6  1.7 0.330-3.034
New G C T  5  1.5 0.308-3.250
New C T G  4  1.1 0.249-4.011
Newm G C G  2  0.6 0.167-6.006
New G  1  0.5 0.130-7.712
New G C G  1  0.3 0.082-12.232
New T  1  0.3 0.073-13.647
New C T  1  0.3 0.068-14.662
New G C G  1  0.3 0.064-15.593
95% CI: 95% confidence interval.
a The name includes the presented sequence of the SNPs investigated in this study and referent alleles of the additional SNPs investigated in the 
study by Pasanen et al. [13] (at positions g.-11187, g.-11110, g.-10499, c.411, c.463 and c.1929).
b,d,e,h,i,j,k The haplotype name includes a sequence of the SNPs investigated in this study and referent alleles in other SNPs investigated in the cited 
study [13], except at the following positions b: c.411 and c.463; d: g.-10499; e: g.-11187; h: g.-11110; i: c.1929; j: g.-11187 and c.1929, and k: 
c.411 and c.463, where the variant alleles exist.
c,f,g,l The haplotype is assigned as new by Pasanen et al. [13], having the same sequence of the SNPs investigated in this study and referent alleles 
at other SNPs investigated in the cited study [13], except at the following positions c: g.-11110, c.411 and c.463; f: g.-11187; g: g.-10499, and l: 
c.411, c.463 and c.1929, where variant alleles exist.
m The haplotype is assigned as new by Pasanen et al. [13], having the same sequence of the SNPs investigated in this study and referent alleles in 
additional SNPs investigated in the cited study.
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transported by OATP1B1 is a persistent motivation 
for scientific research. To the best of our knowledge, 
this is the first study in which polymorphisms con-
tained in the SLCO1B1 gene were studied in the popu-
lations living in the Western Balkan Peninsula. For 
this reason, commonly seen mutations (c.388A>G, 
c.521T>C, c.571T>C, c.597C>T, c.*439 T>G) as 
well as coding region SNPs that were not identified 
in the Caucasian (European) population (c.1086C>T, 
c.1463G>C) were selected for genotyping. Our data 
confirmed that SLCO1B1 is highly polymorphic and 
that several variants appear at a high frequency, both 
in the Macedonian and Albanian populations. The 
SNPs c.388A>G (Asn130Asp), c.571T>C (Leu-
191Leu), c.597C>T (Phe199 Phe) and c.*439T>G, 
all occurred with an allelic frequency between 40.0 
and 65.0%. The non synonymous c.521T>C SNP, 
which has been constantly associated with a re-
duced OATP1B1 activity, was found with an allele 
frequency of approximately 14.0 and 12.0% in the 
Macedonian and Albanian population, respectively, 
which is nearly equal to that reported for Caucasians 
(15.0%) [32], slightly lower than that reported previ-
ously for Dutch (18.0%) [33], Finish (20.0%) [13], 
Table 6. Alignment and frequencies of the SLCO1B1 haplotypes in 94 Albanian subjects.
SLCO1B1 Haplotype c.388A>G
c.521
T>C
c.571
T>C
c.597
C>T
c.1086
C>T
c.1463
G>C
c.*439
T>G Haplotypes Found
Reference A T T C C G T n % 95% CI
*1J/*1K/*1La C 45 26.6 0.618-1.618
*18b/Newc G C T G 21 12.4 0.525-1.905
*1G/*1Ha/Newf/Newg G T G 19 11.5 0.514-1.947
*1J/*1K/*1La C G 11  6.7 0.424-3.344
*1Aa/*1Eh/Newf  8  5.1 0.380-2.630
*1B/*1Fa/Newf G G  6  3.8 0.330-0.301
*5a/Newf C T G  6  3.7 0.322-3.103
New C T G  6  3.5 0.316-3.162
New G  5  3.2 0.297-3.370
New G C  5  3.0 0.286-3.497
New C C T  4  2.9 0.280-3.573
*20i/*21j/Newf G T  4  2.7 0.268-3.734
*1B/*1F G  4  2.5 0.259-3.865
*15a/*16k/*17l G C T G  4  2.4 0.251-3.990
New T  3  2.2 0.236-4.236
Newm G C G  3  1.9 0.212-4.716
New C T  3  1.9 0.210-4.755
New G C C T  2  1.4 0.168-5.938
New G C T  1  1.0 0.114-8.806
New C  1  0.7 0.082-12.179
Newm C G  1  0.6 0.065-15.451
95% CI: 95% confidence interval.
a The name includes the presented sequence of the SNPs investigated in this study and referent alleles of the additional SNPs investigated in the 
study by Pasanen et al. [13].
b,h,i,j,k,l The haplotype name includes a sequence of the SNPs investigated in this study and referent alleles in other SNPs investigated in the cited 
study [13], except at the following positions b: c.411 and c.463; h: g.-11110; i: c.1929; j: g.-11187 and c.1929; k: g.-10499; and l: g.-11187, 
where variant alleles exist.
c,f,g The haplotype is assigned as new by Pasanen et al. [13], having the same sequence of the SNPs investigated in this study and referent alleles 
in other SNPs investigated in the cited study, except at the following positions c: g.-11110, c.411 and c.463; f: g.-11187; and g: g.-10499, where 
variant alleles exist.
m The haplotype is assigned as new by Pasanen et al. [13], having the same sequence of the SNPs investigated in this study and referent alleles at 
additional SNPs investigated in the cited study (at positions g.-11187, g.-11110, g.-10499, c.411, c.463 and c.1929).
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Algerian (17.0%) [11], Israeli (20.0%) [11], Japa-
nese (16.0-19.0%) [11,34] and Korean (25.0%) [35] 
ethnic groups, and much higher than that reported 
for African Americans (2.3%) [12] and Sub-Saha-
ran Africans (1.9%) [11] (Table 4). So far, literature 
data point to equal allele frequency for this SNP in 
Macedonians and European Americans [12] and Han 
Chinese [29], although a lower number of subjects 
in the last two groups was included in the study. The 
same was observed in Albanian and Turkish subjects, 
with an equal number of subjects in the study [36]. 
Compared to studies with Native Americans, Cauca-
sian Europeans, Sub-Saharan Africans, Japanese and 
Israeli subjects [11], the variant alleles found in the 
Macedonian and Albanian subjects were lower for 
c.388A>G (41.0-42.0% vs. 46.0-79.0%), higher for 
c.571 T>C (62.0-65.0% vs. 13.0-61.0%) and nearly 
equal for c.597C>T (40.0-45.0% vs. 42.0-50.0%), 
with the exception of Native Americans in which a 
much lower allele frequency was observed (28.0%). 
The allele frequency for SNP c.*439T>G was lower in 
comparison with Sub-Saharan Africans (47.0-50.0% 
vs. 76.0%), higher than that of Caucasian Europeans 
(30.0%) and almost equal to the frequency of other 
ethnic groups, where a variant G allele existed with 
a frequency between 41.0% (Native Americans) and 
55.0% (Israeli) (Table 4). No variant alleles were 
found for c.1086C>T and c.1463G>C SNPs in the 
Macedonian and Albanian populations and the same 
was observed in German, Finish, Japanese, Israeli and 
Turkish subjects [11,36], while in the studied Native 
American and Sub-Saharan African, Ugandan and 
Pakistani ethnic groups, a low frequency of variant 
alleles was observed, between 1.0 and 7.0% for vari-
Figure 1. Pairwise LD profiles for SLCO1B1 SNPs in Macedonians (n = 266); r2 cells (below the diagonal, A) and 
D’ (cells above the diagonal, B) values for each pair of the seven SNPs are presented.
c.388A>G c.521T>C c.571T>C c.597C>T c.1086C>T c.1463G>C c.*439T>G
c.388A>G 0.698 0.487 0.740 0.000 0.000 0.613
c.521T>C 0.113 0.919 0.872 0.000 0.000 0.645
c.571T>C  0.187 0.233 0.520 0.000 0.000 0.426
c.597C>T  0.531 0.178 0.218 0.000 0.000 0.699
c.1086C>T 0.000 0.000 0.000 0.000 0.000 0.000
c.1463G>C 0.000 0.000 0.000 0.000 0.000 0.000
c.*439T>G  0.289 0.072 0.115 0.373 0.000 0.000
D’
r2
A B
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ant T in c.1086C>T and 0.5 and 3.0% for variant C 
in c.1463G>C [11].
For all SNPs, the distributions of the genotypes 
did not differ significantly (p >0.05) between healthy 
subjects and patients and between male and female 
subjects. These data are partly in accordance with the 
results obtained in the study of Hubacek et al. [37], 
in which no difference for genotype distributions of 
rs4149056 variant between male and female subjects 
was observed. However, the results of the same study 
pointed to possible gender-dependent effects of this 
SNP within the SLCO1B1 gene on statin treatment 
efficacy.
It is increasingly evident that the most relevant 
variants, the SNPs 388A>G and 521C>T, have a 
major effect on OATP1B1 activity. However, their 
association and other SNPs in LD with these func-
tionalities may modify the respective phenotype and 
explain the discrepant effects of some SNPs on OAT-
P1B1 activity in vivo. Most of the literature data point 
to a strong association between this SNP pair and its 
effect on drug response [20,29]. In the actual study, 
the association between c.388A>G and c.521 T>C 
was relatively weaker compared to other SNP pairs, 
especially those in the Albanian population. These 
data and generally, the differences between the two 
populations in LD data, are probably explained by 
the significantly smaller number of Albanian subjects 
included in the study and random sampling variation. 
The c.521T>C SNP showed the strongest correlation 
with the c.597C>T in both populations and the similar 
results have been obtained in the study of Pasanen et 
al. [13], in which a large sample (468) of Caucasian 
subjects was included.
Figure 2. Pairwise LD profiles for SLCO1B1 SNPs in Albanians (n = 94); r2 cells (below the diagonal, A) and D’ 
(cells above the diagonal, B) values for each pair of the seven SNPs are presented.
D’
r2
A B
c.388A>G c.521T>C c.571T>C c.597C>T c.1086C>T c.1463G>C c.*439T>G
c.388A>G 0.219 0.370 0.498 0.000 0.000 0.477
c.521T>C 0.009 0.635 0.746 0.000 0.000 0.238
c.571T>C  0.119 0.091 0.206 0.000 0.000 0.137
c.597C>T  0.221 0.097 0.031 0.000 0.000 0.505
c.1086C>T 0.000 0.000 0.000 0.000 0.000 0.000
c.1463G>C 0.000 0.000 0.000 0.000 0.000 0.000
c.*439T>G 0.169 0.008 0.011 0.214 0.000 0.000
19
BALKAN JOURNAL OF MEDICAL GENETICS
Daka Grapci A, Dimovski AJ, Kapedanovska A, Vavlukis M, Eftimov A, Matevska Geshkovska N, 
Labachevski N, Jakjovski K, Gorani D, Kedev S, Mladenovska K
Compared with the analysis performed with 
single SNPs, haplotypes often better predict the as-
sociated phenotype. In the present study, the most 
common SLCO1B1 haplotype, *IJ/*IK/*IL, con-
tained the synonymous c.571 T>C SNP as compared 
with the reference sequence. It occurred at a fre-
quency (35.6%) similar to that reported in the study 
of Pasanen et al. [13]. The c.521T>C SNP existed 
in two (*5 and *15/*16/*17) major haplotypes in 
the Macedonian and Albanian populations and one 
new, identified in the Albanian population only. Both 
common haplotypes, with a frequency of 2.0 and 
3.7% (for *5) and 2.4 and 8.6% (for *15/*16/*17) in 
the Macedonian and Albanian subjects, respectively, 
contained the c.597C>T and c.439T>G SNPs. In the 
new haplotype identified in the Albanian population, 
instead of variant G allele in the c.439T>G SNP, vari-
ant C allele of c.571T>C existed, with referent alleles 
in other SNPs. Considering the significantly smaller 
number of subjects in the Albanian population, as 
potential limitation of this study, this result should 
be confirmed in a study in which a larger number of 
Albanian subjects would be included. The frequen-
cies of the major haplotype *15/*16/*17 containing 
the variant alleles of the functionally most signifi-
cant SNP pair c.388A>G/ c.521T>C (8.6 and 2.4% 
for Macedonians and Albanians, respectively) were 
lower than the frequency of haplotype *15 reported 
for Chinese (14.0%) and Japanese (15.8%), higher 
for Macedonians and comparable for Albanians with 
that of Caucasians (2.4%) and significantly higher 
than the one of African Americans (0.0%) [13,29].
In conclusion, this study presents an extensive 
analysis of SLCO1B1 variant genotype and haplo-
type distribution in selected populations living in 
the Western Balkan Peninsula, Macedonians and 
Albanians for the first time. No significant differ-
ences (p >0.05) in allelic frequencies and genotype 
distributions of the analyzed SNPs were observed 
between the two ethnic groups and the data are similar 
to those for Caucasians. About 8.6 and 2.4% of the 
Macedonians and Albanians, respectively, carrying 
the SLCO1B1*15 or SLCO1B1*16 or SLCO1B1*17 
variant may exhibit altered/impaired transport activ-
ity of OATP1B1.
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